CTCX רווח נקי למניה ב-12 החודשים האחרונים carmellrx.com

The erosion of patent protection due to a shift toward the mass-market cosmetics segment creates risks, as evidenced by the rolling earnings per share over the year, where the 0.00 level records fresh values. Carmell Corporation (CTCX) bases its operations on innovative plasma materials for tissue regeneration, with development conducted in collaboration with clinics and tissue banks to accelerate patient rehabilitation.
פילוחים אנליטיים ודוחות נתונים של חברת Carmell Therapeutics (CTCX)

Earnings per share (EPS TTM) measures the portion of profit allocated to each security over a trailing twelve-month period. This metric reflects actual capital generation efficiency by excluding the impact of the total issuance volume. By analyzing the EPS TTM annual snapshot, an investor determines the sustainability of the asset's yield. For Carmell Corporation (CTCX), the negative trend confirms the pressure of losses and high rebranding costs. Risks associated with shifting the business model toward bio-cosmetics directly reduce the firm's liquidity.